Sign In
Buy CCXI
$13.86
-0.140 (-1.00%)
At Close: Jul 31, 2026
Why ChemoCentryx Stock Is On Fire Today
10:08am, Thursday, 04'th Aug 2022
The rare-disease specialist is being bought out at a sizable premium.
Amgen to gain rare-disease drug in $3.7 billion acquisition of ChemoCentryx
08:24am, Thursday, 04'th Aug 2022
Amgen Inc. AMGN, +1.32% said Thursday it plans to buy ChemoCentryx Inc. CCXI, +3.61% for $3.7 billion in cash. The deal will give Amgen access to Tavneos, a treatment for ANCA-associated vasculitis th
ChemoCentryx to Hold Second Quarter 2022 Financial Results Conference Call on Tuesday, August 9, 2022
04:05pm, Tuesday, 02'nd Aug 2022
SAN CARLOS, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's second quarter 2022 financial results will be released after market close o
ChemoCentryx's (CCXI) Tavneos Aids Growth, Overdependence a Woe
01:59pm, Tuesday, 05'th Jul 2022
ChemoCentryx (CCXI) has only one product approved for sale in its portfolio, Tavneos. Nevertheless, it is progressing well with the clinical development of its pipeline candidates.
ChemoCentryx to Present at the H.C. Wainwright Global Investment Conference
08:30am, Monday, 16'th May 2022
SAN CARLOS, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the H.C. W
SAN CARLOS, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced upcoming presentations at three key medical conferences that will highlight findings from the p
ChemoCentryx: A Biotech Stock Well Worth the Risk
04:00am, Monday, 09'th May 2022
In the wake of its first quarter earnings report, ChemoCentryx ran as much as 25% on Friday as the broader market fell. The move could mark an important inflection point for a stock that had been in a
ChemoCentryx (CCXI) Q1 Earnings and Sales Miss Estimates
05:18pm, Friday, 06'th May 2022
ChemoCentryx (CCXI) posts a wider-than-anticipated Q1 loss and a revenue lag. However, product sales of CCXI's recently approved drug Tavneos grow five-fold from the previous quarter's levels.
Why ChemoCentryx Shares Are Popping Off
11:33am, Friday, 06'th May 2022
ChemoCentryx Inc (NASDAQ: CCXI) shares are trading higher by 21.45% at $19.00 after the company reported first-quarter results. ChemoCentryx reported quarterly losses of 55 cents per share which misse
ChemoCentryx, Inc. (CCXI) CEO Dr. Thomas Schall on Q1 2022 Results - Earnings Call Transcript
08:35pm, Thursday, 05'th May 2022
ChemoCentryx, Inc. (NASDAQ:CCXI ) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Dr. Thomas Schall – Chairman, President and Chief Executive Officer Tausif Butt – Exe
ChemoCentryx (CCXI) Reports Q1 Loss, Misses Revenue Estimates
08:19pm, Thursday, 05'th May 2022
ChemoCentryx (CCXI) delivered earnings and revenue surprises of -83.33% and 78.77%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
ChemoCentryx to Hold First Quarter 2022 Financial Results Conference Call on Thursday, May 5, 2022
08:30am, Thursday, 28'th Apr 2022
SAN CARLOS, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's first quarter 2022 financial results will be released after market close o
Why Is ChemoCentryx (CCXI) Up 1.8% Since Last Earnings Report?
12:47pm, Thursday, 31'st Mar 2022
ChemoCentryx (CCXI) reported earnings 30 days ago. What's next for the stock?
2 Stocks Down 30% in 2022 That Are Great Buys Right Now
11:30am, Wednesday, 30'th Mar 2022
Years from now you could be thanking yourself for buying shares of these two companies today.
Bonds Are Screaming “Recession.” That's Great News For One Top Sector.
04:44pm, Tuesday, 29'th Mar 2022
The 10-2 year treasury yield spread is close to zero. Here's what you should do about this warning sign of a coming recession.
